Medicare Advantage and Part D Plans Restrict Ondansetron Access

Medicare Plans restrict Access to Affordable ⁢Antiemetic, ⁢Study Finds

Millions of⁢ Americans‍ wiht cancer face hurdles accessing a low-cost anti-nausea medication due⁢ to restrictive policies in Medicare Advantage and Part D plans, a new study reveals.

Despite⁢ ondansetron being available as a generic since 2006, researchers found that these plans frequently employ prior authorization⁤ requirements and quantity⁢ limits, perhaps delaying treatment and increasing administrative burdens⁤ for‍ both patients⁤ and healthcare providers.

The‍ study,published ⁣in JAMA Network open,analyzed data from ⁢over 4,300 Medicare ⁤prescription drug plans,encompassing both Part D‍ and‍ Medicare Advantage.Researchers examined the⁣ use of utilization management ⁣tools and costs for oral ondansetron, a commonly prescribed medication to prevent nausea and vomiting associated with chemotherapy.

Barriers to Access:

Prior Authorization: Medicare Advantage⁤ plans were significantly more likely to require prior authorization for ondansetron⁤ (90.3%) compared to Part D‍ plans (71.9%).
Quantity Limits: ⁣ Medicare Advantage plans also imposed quantity limits on⁢ ondansetron prescriptions ⁣more frequently enough (22.5%) than Part ⁣D plans (16.5%).

Cost Discrepancies:

While Medicare Advantage plans⁤ offered lower costs for 4-mg and 8-mg ondansetron⁢ tablets compared to Part D plans, both plan types⁣ charged significantly more than the Mark Cuban⁤ Cost Plus⁢ Drug Company, a direct-to-consumer pharmacy known ‍for its transparent pricing.

Such as, a 30-day supply of⁣ 4-mg ondansetron tablets cost $24.40 ⁣in Medicare Advantage plans and $31.40 in Part D plans,⁢ compared to just $9.50 through the Cost Plus drug Company.

Call for Policy Changes:

The⁤ study authors emphasize the need for policymakers to address these access barriers and prioritize patient⁤ well-being.

“Despite ⁢ondansetron’s decreasing costs, most Medicare Advantage and Part D prescription drug plans continue to enforce substantial utilization management, limiting patients’ timely access while increasing clinicians’ administrative burdens,” the authors wrote.”Policymakers must prioritize access to high-value medications to prevent unneeded delays and cost in care.”

Study Details:

This cross-sectional study utilized data from the Centers for Medicare &⁤ Medicaid Services database⁣ for the third quarter of 2023. Researchers analyzed 813 part D and 3,512 Medicare Advantage prescription drug plans.

Limitations:

The study relied⁢ on ‍plan-level data, limiting insights into individual patient experiences and the⁢ real-world impact of these policies.Funding:

Two authors received support from ‍the University of Texas Southwestern Medical⁣ Center and the national Cancer Institute. Several authors disclosed receiving⁤ grants, personal fees, and other ties with various sources.

Barriers to Affordable Nausea Relief: Study Highlights Medicare Plan Restrictions on Ondansetron Access ⁤

NewsDirectory3.com -⁣ Millions of Americans with cancer face important obstacles in accessing an affordable anti-nausea medication due to restrictive policies implemented by Medicare Advantage and Part⁣ D plans, according‍ to a recent study⁢ published in JAMA Network Open. Ondansetron, a widely prescribed drug to prevent nausea and vomiting associated with ⁢chemotherapy, has been available as a generic since 2006. Though, the study reveals that ⁤these plans frequently employ prior authorization requirements and quantity limits for this essential medication, potentially delaying treatment and burdening both patients and healthcare providers with administrative complexities.

Key Findings:

Prior Authorization Hurdles: Medicare Advantage ⁢plans⁣ were found to⁢ be considerably more likely (90.3%) to require prior authorization ⁤for ‍ondansetron compared to Part D plans (71.9%).

Quantity Limits‍ Imposed: Medicare Advantage⁢ plans also implemented quantity limits on ondansetron prescriptions more frequently (22.5%) than Part⁤ D⁣ plans (16.5%).

* Cost Discrepancies: While Medicare Advantage plans offered slightly lower costs for 4-mg and 8-mg ondansetron tablets compared to⁢ Part D plans, both plan⁤ types charged considerably more than the Mark cuban Cost⁢ Plus Drug Company, a direct-to-consumer‍ pharmacy known for its transparent pricing. For example, a 30-day supply of 4-mg ondansetron tablets cost $24.40 in Medicare Advantage plans and $31.40 in Part⁤ D plans, compared to only $9.50 through the Cost ‍Plus Drug Company.

The study, ⁢which analyzed data⁤ from over 4,300 ⁤Medicare prescription drug plans, emphasizes the urgent need for policy changes to⁣ address these access barriers and prioritize patient ⁢well-being.

“Despite ondansetron’s decreasing ⁢costs, most‍ Medicare Advantage and Part D prescription drug plans continue to enforce substantial utilization management, limiting patients’ timely access⁣ while increasing clinicians’ administrative burdens,” the study authors wrote.

“Policymakers must prioritize access to high-value medications to prevent unneeded delays and cost in care.”